Steven R. DeMeester, M.D.
disclosures–22 sec
BE incidence–30 sec https://www.ncbi.nlm.nih.gov/pubmed/15366737
HGD–1:18
issues to consider–2:25
endotherapy candidates–2:44
low risk submucosal invasion–3:31 https://www.
Keyword(s): AIM II, BE, cryospray ablation, CSA Medical, depth of invasion, EGD, en-bloc resection, endoscopic resection, endoscopic tx, endotherapy, esophageal adenocarcinoma, esophagectomy, EUS, Halo 360, HGD, IM, intramucosal cx, lap Nissen, LGD, LN metastases, NBI, reflux, RFA, surveillance, UE, VSE